UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
SCHEDULE
14C INFORMATION
Information
Statement Pursuant to Section 14C
of
the Securities Exchange Act of 1934, as amended
[X]
Filed by the Registrant
|
[ ]
Filed by a Party other than the Registrant
|
Check
the appropriate box:
[X]
|
Preliminary
Information Statement
|
[ ]
|
Definitive
Information Statement
|
[ ]
|
Confidential,
for Use of the Commission (as permitted by Rule 14c)
|
PETLIFE
PHARMACEUTICALS, INC.
(Name
of Registrant as Specified in its Charter)
Name
of Person(s) Filing Information Statement, if other than Registrant:
N/A
Payment
of Filing Fee (Check the appropriate box):
[X]
|
|
No
Fee Required.
|
|
|
|
[ ]
|
|
Fee
based on table below per Exchange Act Rules 14C-5(g) and 0-11
|
|
|
|
(1)
|
|
Title
of each class of securities to which transaction applies: _____________________________.
|
|
|
|
(2)
|
|
Aggregate
number of securities to which the transaction applies: _________________________.
|
|
|
|
(3)
|
|
Per
unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11
|
|
|
(Set
forth the amount of the filing fee is calculated and state how it was determined: ____.
|
|
|
|
(4)
|
|
Proposed
maximum value of transaction: ____________________________________________.
|
|
|
|
(5)
|
|
Total
fee paid:_________________________________________________________________.
|
|
|
|
[ ]
|
|
Fee
paid previously with preliminary materials.
|
|
|
|
[ ]
|
|
Check
box if any part of the fee is offset as provided by Exchange Rule 0-11 (a) (2) and identify the filing fee for which the offsetting
fees was paid previously. Identify the previous filing by registration number, or the Form or Schedule and the date of its
filing.
|
WE
ARE NOT ASKING YOU FOR A PROXY
AND
YOU ARE REQUESTED NOT TO SEND US A PROXY.
PETLIFE
PHARMACEUTICALS, INC.
10120
So. Eastern Avenue
Suite
213
Henderson,
NV 89052
INFORMATION
STATEMENT
This
Information Statement (the “
Information Statement
”) is being furnished to all holders of shares of Common Stock,
par value $0.001 per share (“
Common Stock”)
of record at the close of business on April 25, 2018 (collectively,
the “
Stockholders
”) of PetLife Pharmaceuticals, Inc., a Nevada corporation (the “
Company
”),
with respect to a proposed corporate action of the Company. This Information Statement is first being provided to the Stockholders
on or about __________________.
The
corporate action involves one (1) proposal (the “
Proposal
”) providing for the following:
1.
To approve the increase in the total number of authorized shares of common stock from Seven Hundred Fifty Million (750,000,000)
to Ten Billion (10,000,000,000).
ONLY
THE STOCKHOLDERS OF RECORD AT THE CLOSE OF BUSINESS ON APRIL 25, 2018 ARE ENTITLED TO NOTICE OF THE PROPOSAL. A PRINCIPAL STOCKHOLDER
WHO HOLDS FIFTY-FOUR AND 53/100 PERCENT (54.3%) OF THE COMPANY’S SHARES OF VOTING CAPITAL STOCK ENTITLED TO VOTE ON THE
PROPOSAL HAS VOTED IN FAVOR OF THE PROPOSAL. AS A RESULT, THE PROPOSALS HAVE BEEN APPROVED WITHOUT THE AFFIRMATIVE VOTE OF ANY
OTHER STOCKHOLDERS OF THE COMPANY.
BY
ORDER OF THE BOARD OF DIRECTORS
By:
|
/s/
Laura De Leon Castro
|
|
|
Laura
De Leon Castro, Secretary
|
|
Henderson,
Nevada
_____________________,
2018
TABLE
OF CONTENTS
PETLIFE
PHARMACEUTICALS, INC.
10120
So. Eastern Avenue
Suite
213
Henderson,
NV 89052
INFORMATION
STATEMENT
This
Information Statement (this “
Information Statement
”) contains information related to certain corporate actions
of PetLife Pharmaceuticals, Inc., a Nevada corporation (the “
Company
”), and is expected to be mailed on or
about _____________, 2018__ to all holders of shares of Common Stock, par value $0.001 per share (“
Common Stock
”)
of record at the close of business on April 25, 2018 (collectively, the “
Stockholders
”)
ABOUT
THE INFORMATION STATEMENT
What
Is The Purpose Of The Information Statement?
This
Information Statement is being provided pursuant to Section 14 of the Securities Exchange Act of 1934, as amended, to notify the
Stockholders, as of the close of business on April 25, 2018 (the “
Record Date
”), of the corporate actions taken
pursuant to the written consent of certain principal stockholders.
Specifically,
on April 25, 2018, a holder of Fifty-Four and 53/100 percent (54.3%) our Common Stock voted to approve the corporate matters outlined
in this Information Statement, consisting of: (i) To approve an increase in the number of authorized shares of Common Stock from
Seventy-five Million (75,000,000) to Ten Billion (10,000,000,000).
Who
Is Entitled To Notice?
All
holders of shares of Common Stock on the close of business on the Record Date will be entitled to notice of each matter
voted upon by a principal stockholder pursuant to the written consent of a principal stockholder. Specifically, the holder of
a majority of the outstanding shares of Common Stock, which constitute a majority of all shares eligible to vote, has voted
in favor of the Proposal listed in this notice. Under Nevada corporate law Section NRS 78.320, all the activities requiring
stockholder approval may be taken by obtaining the written consent and approval of more than a majority (greater than 50.00%)
of the holders of voting stock in lieu of a meeting of the stockholders.
Because
the holder of more than fifty percent, i.e., 54.3% of the collective voting rights of the Common Stock, voted in favor of the
Proposal no action by the minority stockholders in connection with the Proposal set forth herein is required.
PRINCIPAL
STOCKHOLDER
Who
Are The Principal Stockholders And How Many Votes Are They Entitled to Cast?
Delta
9 Pharmaceuticals, Inc. is the holder of 100,000,000 shares of Common Stock. The voting rights of Delta 9 Pharmaceuticals, Inc.
represent 54.3% of the total issued and outstanding voting rights of the Company.
What
Corporate Matters Have The Principal Stockholders Voted For?
The
principal stockholder that holds a greater than a majority, 54.3% of the total issued and outstanding voting rights of the Company
has voted by written consent for the approval and ratification of both of the Board of Directors proposal described in this Information
Statement. (1)
Series
of Stock
|
|
Shareholder
|
|
Shares
in Series
|
|
|
Percent
of
Ownership
in
Series
|
|
|
Percent
of
All
Voting
Rights
|
|
Common Stock
|
|
Delta 9 Pharmaceuticals, Inc.
|
|
|
100,000,000
|
|
|
|
54.3
|
%
|
|
|
54.3
|
%
|
Notes:
(1)
Based on a total of 183,358,884 shares of Common Stock issued and outstanding as of April 25, 2018. Under Rule 13d-3, certain
shares may be deemed to be beneficially owned by more than one person (if, for example, persons share the power to vote or the
power to dispose of the shares). In addition, shares are deemed to be beneficially owned by a person if the person has the right
to acquire the shares (for example, upon exercise of an option) within 60 days of the date as of which the information is provided.
In computing the percentage ownership of any person, the amount of shares outstanding is deemed to include the amount of shares
beneficially owned by such person (and only such person) by reason of these acquisition rights. As a result, the percentage of
outstanding shares of any person as shown in this table may not necessarily reflect the person’s actual ownership or voting
power with respect to the number of shares of common stock actually outstanding on April 25, 2018.
What
is the Recommendation of the Board of Directors?
On
April 24, 2018, the Board of Directors unanimously adopted resolutions approving the Proposal. The Board of Directors recommends
adoption of the Proposal.
What
Vote is Required to Approve the Proposal?
A
vote of the majority of the voting rights of capital stock is required to approve the Proposal. As a result, a vote to approve
the Proposal by a majority of the aggregate voting rights held by a holder of Common Stock is sufficient to approve the Proposal.
In this instance, 54.3% of the voting right of the outstanding shares of voting stock have approved the Proposal.
PRINCIPAL
OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT
Security
Ownership
The
following tables set forth certain information concerning the number of shares of our capital stock owned beneficially as of April
25, 2018 by: (i) each person (including any group) known to us to own more than five percent (5%) of any Series of our voting
securities, (ii) our directors, and our named executive officers. Unless otherwise indicated, the stockholders listed possess
sole voting and investment power with respect to the shares shown.
Title
of Series
|
|
Name
and Address of Beneficial Owner
|
|
Amount
and
Nature
of
Beneficial
Ownership
|
|
|
Percentage
of Ownership(1)
|
|
|
|
|
|
|
|
|
|
|
|
|
Common
Stock
|
|
Laura De
Leon Castro (2)
Chief Executive Officer, President,
Secretary, Treasurer, Principal Financial
Officer, and Director
|
|
|
-0-
|
|
|
|
-0-
|
|
|
|
|
|
|
|
|
|
|
|
|
5%
SHAREHOLDERS
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Common
Stock
|
|
Delta 9 Pharmaceuticals,
Inc.
333 City Blvd. West
Suite 1700
Orange, CA 92868
|
|
|
100,000,000
(Direct)
|
|
|
|
54.3
|
%
|
|
|
|
|
|
|
|
|
|
|
|
Common
Stock
|
|
Grand Street Ventures
LLC
3 Grand Street
Hanock, MD 21750
|
|
|
18,700,000
(Direct)
|
|
|
|
10.2
|
%
|
|
|
|
|
|
|
|
|
|
|
|
Common
Stock
|
|
Elite International
Partners, Inc.
8233 Roxbury Road
Los Angeles, CA 90069
|
|
|
3,100,000
(Direct)
|
|
|
|
7.14
|
%
|
Notes:
(1)
Based on 183,358,884 shares of our Common Stock, issued and outstanding on April 25, 2018. Under Rule 13d-3, certain shares may
be deemed to be beneficially owned by more than one person (if, for example, persons share the power to vote or the power to dispose
of the shares). In addition, shares are deemed to be beneficially owned by a person if the person has the right to acquire the
shares (for example, upon exercise of an option) within 60 days of the date as of which the information is provided. In computing
the percentage ownership of any person, the amount of shares outstanding is deemed to include the amount of shares beneficially
owned by such person (and only such person) by reason of these acquisition rights. As a result, the percentage of outstanding
shares of any person as shown in this table may not necessarily reflect the person’s actual ownership or voting power with
respect to the number of shares of common stock actually outstanding on April 25, 2018.
(2)
The address is 10120 So. Eastern Avenue, Suite 213, Henderson, NV 89052.
DIRECTORS,
EXECUTIVE OFFICERS, PROMOTERS AND CONTROL PERSONS
We
have no promoters and we have no control persons required to be disclosed other than those listed above.
Our
executive officers and directors and their ages and titles as of April 25, 2018 are as follows:
Name and Address of Officer/Director
(1)
|
|
Age
|
|
Position
|
Laura
De Leon Castro
|
|
43
|
|
Chief
Executive Officer, President, Secretary, Treasurer. Principal Financial Officer, and Chairman of the Board of Directors
|
Notes:
(1) The address is 10120 So. Eastern Avenue, Suite 213, Henderson, NV 89052.
Laura
De Leon Castro - Chief Executive Officer, President, Secretary, Treasurer, Principal Financial Officer, and Chairman of the Board
of Directors
Laura
De Leon Castro, age 43, was elected as Chief Executive Officer, President, Secretary, Treasurer, and Chairman of the Board of
Directors on March 19, 2018. She was born and raised in the City of Monterrey, Mexico. She is a graduate of the law School of
the University of Monterrey. Following her graduation in 1996, she was employed as attorney with a law firm in Monterrey, Mexico
from 1997 to 2000. Thereafter, she served as the Assistant to the Chief Executive Officer of Gatorade Mexico from 2001 to 2003.
During that period, she also became a certified Emergency Medical Technician. Following move to Spain in 2003, she has served
as a volunteer Emergency Medical Technician.
Term
of Office
Members
of our board of directors are appointed to hold office until the next annual meeting of our stockholders or until his or her successor
is elected and qualified, or until he or she resigns or is removed in accordance with the provisions of the Nevada Revised Statutes.
Our officers are appointed by our board of directors and hold office until removed by the board.
Involvement
in Certain Legal Proceedings
None
of our directors or executive officers has been, during the past ten years:
(i)
involved in any bankruptcy petition filed by or against such person or any business of which such person was a general partner
or executive officer, either at the time of the bankruptcy or within two years prior to that time;
(ii)
convicted of any criminal proceeding or subject to a pending criminal proceeding (excluding traffic violations and other minor
offenses);
(iii)
subject to any order, judgment, or decree, not subsequently reversed, suspended or vacated, of any court of competent jurisdiction,
permanently or temporarily enjoined, barred, suspended or otherwise limited from involvement in any type of business, securities,
futures, commodities or banking activities;
(iv)
found by a court of competent jurisdiction (in a civil action), the Securities and Exchange Commission or the Commodity Futures
Trading Commission to have violated a federal or state securities or commodities law, and the judgment has not been reversed,
suspended, or vacated;
(v)
found by a court of competent jurisdiction in a civil action or by the Commission to have violated any Federal or State securities
law, and the judgment in such civil action or finding by the Commission has not been subsequently reverse, suspended, or vacated;
(vi)
subject of, or a party to, any Federal or State judicial or administrative order, judgment, decree, or finding, not subsequently
reversed, suspended or vacated, related to an alleged violation of securities or commodities law or regulation; any law or regulation
respecting financial institutions or insurance companies; or any law or regulation prohibiting mail or wire fraud or fraud in
connection with any business entity; or
(vii)
the subject of, or a party to, any sanction or order, not subsequently reversed, suspending or vacated, of any self-regulatory
any registered entity of the Commodity Exchange Act or any equivalent exchange, association, entity or organization that has disciplinary
authority over its members or persons associated with a member.
Significant
Employees
We
have no significant employees, other than our executive officer.
Committees
of the Board of Directors
We
do not presently have a separately constituted audit committee, compensation committee, nominating committee, executive committee
or any other committees of our board of directors.
Audit
Committee Financial Expert
Not
applicable, as we do not presently have an audit committee.
Director
Independence
Quotations
for our common stock are entered on the OTC Bulletin Board inter-dealer quotation system, which does not have director independence
requirements. For purposes of determining director independence, we have applied the definitions set out in NASDAQ Rule 4200(a)(15).
Under NASDAQ Rule 4200(a)(15), a director is not considered to be independent if he or she is also an executive officer or employee
of the corporation. Our sole director acts as an executive officer of the corporation.
Board
Meetings and Committees, Annual Meeting Attendance
Although
we intend to establish an audit committee and compensation committee, our board of directors has not adopted any committees to
the board of directors. Our board of directors held no formal meeting during the most recently completed fiscal year. All other
proceedings of the board of directors were conducted by resolutions consented to in writing by all the directors and filed with
the minutes of the proceedings of the directors. Such resolutions consented to in writing by the directors entitled to vote on
that resolution at a meeting of the directors are, according to the corporate laws of the State of Nevada and our bylaws, as valid
and effective as if they had been passed at a meeting of the directors duly called and held.
At
each annual meeting of shareholders, directors will be elected by the holders of common stock to succeed those directors whose
terms are expiring. Directors will be elected annually and will serve until successors are duly elected and qualified or until
a director’s earlier death, resignation or removal. Our bylaws provide that the authorized number of directors may be changed
by action of the majority of the board of directors or by a vote of the shareholders of our Company. Vacancies in our board of
directors may be filled by a majority vote of the board of directors with such newly appointed director to serve until the next
annual meeting of shareholders, unless sooner removed or replaced. We currently do not have a policy regarding the attendance
of board members at the annual meeting of shareholders.
Code
of Ethics
Given
our limited operations, we have not adopted a Code of Ethic that applies to our officers, directors and employees in accordance
with applicable federal securities laws. We expect that our Board of Directors will adopt a Code of Ethics in the near future.
Compliance
with Section 16(a) of the Exchange Act
Section
16(a) of the Exchange Act requires our executive officers and directors, and persons who own more than 10% of any publicly traded
class of our equity securities, to file reports of ownership and changes in ownership of our equity securities with the SEC. Officers,
directors, and greater than ten percent stockholders are required by SEC regulation to furnish the Company with copies of all
Section 16(a) forms that they file.
Based
solely on the reports received and on the representations of the reporting persons, we believe that our current officer and sole
director has not yet complied with all applicable filing requirements of Section 16(a) of the Exchange Act during the current
fiscal year, but is currently in the process of doing so.
EXECUTIVE
COMPENSATION
Summary
of Compensation
We
paid no compensation to our executive officers and directors during the two quarters ended February 28, 2018.
We
paid compensation to our executive officers and directors during the fiscal year ended August 31, 2017, as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Option
and
|
|
|
All
|
|
|
|
|
Name
and
|
|
|
|
|
|
|
|
Deferred
|
|
|
|
|
|
Stock
|
|
|
Warrant
|
|
|
Other
|
|
|
|
|
Principal
Position
|
|
|
|
|
Salary
|
|
|
Compensation
|
|
|
Bonus
|
|
|
Awards
|
|
|
Awards
|
|
|
Compensation
|
|
|
Total
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Dr.
Ralph Salvagno (1)
|
|
|
2017
|
|
|
$
|
240,000
|
|
|
$
|
-
|
|
|
$
|
-
|
|
|
$
|
112,000
|
|
|
$
|
-
|
|
|
$
|
-
|
|
|
$
|
352,000
|
|
Chief
Executive Officer, Chief Financial Officer and Director
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Dr.
Vivek Ramana (2)
|
|
|
2017
|
|
|
$
|
-
|
|
|
$
|
-
|
|
|
$
|
-
|
|
|
$
|
-
|
|
|
$
|
-
|
|
|
$
|
-
|
|
|
$
|
-
|
|
Chief
Medical Officer
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1)
|
Dr.
Salvagno was appointed as CEO, CFO and Director on June 9, 2016 and resigned on March 22, 2018,
|
|
|
|
|
(2)
|
Dr.
Ramana was appointed as CMO on June 30, 2016.
|
Director
|
|
|
|
|
|
|
Fees Earned
or Paid in
Cash
|
|
|
|
Stock
Awards
|
|
|
|
Warrant
Awards (1)
|
|
|
|
Non-Equity
Incentive
Plan
Compensation
|
|
|
|
Change in Pension
Value and
Nonqualified
Deferred
Compensation
Earnings
|
|
|
|
All Other
Compensation
|
|
|
|
Total
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Vyvyan Campbell (1)
|
|
|
2017
|
|
|
$
|
-
|
|
|
$
|
-
|
|
|
$
|
-
|
|
|
$
|
-
|
|
|
$
|
-
|
|
|
$
|
-
|
|
|
$
|
-
|
|
(1)
Ms. Campbell was appointed as Director on September 6, 2016 and resigned on March 22, 2018.
Outstanding
Equity Awards at Fiscal Year-End
The
Company has granted options to an employee and to a consultant. Options activity for the year ended August 31, 2017 is as follows:
|
|
|
|
|
|
|
|
Weighted
|
|
|
|
|
|
|
|
|
|
Weighted
|
|
|
Average
|
|
|
|
|
|
|
|
|
|
Average
|
|
|
Remaining
|
|
|
Aggregate
|
|
|
|
Number
|
|
|
Exercise
|
|
|
Contractual
|
|
|
Intrinsic
|
|
|
|
of
Options
|
|
|
Price
|
|
|
Terms
|
|
|
Value
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Outstanding at August 31, 2016
|
|
|
4,000,000
|
|
|
$
|
0.25
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Granted
|
|
|
-
|
|
|
$
|
-
|
|
|
|
|
|
|
|
|
|
Exercised
|
|
|
-
|
|
|
$
|
-
|
|
|
|
|
|
|
|
|
|
Forfeited
|
|
|
-
|
|
|
$
|
-
|
|
|
|
|
|
|
|
|
|
Expired
|
|
|
-
|
|
|
$
|
-
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Outstanding at August 31, 2017
|
|
|
4,000,000
|
|
|
$
|
0.25
|
|
|
|
1.77
|
|
|
$
|
369,200
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Exercisable at August 31, 2017
|
|
|
4,000,000
|
|
|
$
|
0.25
|
|
|
|
|
|
|
|
|
|
Employment
Contracts
As
of August 31, 2017 we terminated all employment agreement and, therefore, have no employment contracts, termination of employment
or change-in-control arrangements with any of our executive officers or other employees.
DESCRIPTION
OF SECURITIES
The
current authorized capital stock of our Company consists of Seventy Hundred Fifty Million (750,000,000) shares of Common Stock,
par value $0.001 per share, and Fifty Million (50,000,000) shares of Preferred Stock, par value $0.001 per share. As of April
25, 2018, One Hundred Eighty-three Million, Three Hundred Fifty-eight Thousand, Eight Hundred Eighty-four (183,358,884) shares
of Common Stock were issued and outstanding. As of April 25, 2018, no shares of Preferred Stock were issued and outstanding. The
following description is a summary of the capital stock of our Company and contains the material terms of our voting capital stock.
Additional information can be found in our Certificate of Incorporation and our Bylaws.
Common
Stock
On
April 25, 2018 (the “Record Date”), there were One Hundred Eighty-three Million Three Hundred Fifty-eight Thousand
Eight Hundred Eighty-four (183,358,884) shares of Common Stock issued and outstanding. Each share of Common Stock entitles the
holder to one (1) vote on each matter submitted to a vote of our stockholders, including the election of Directors. There is no
cumulative voting. The holders of our Common Stock are entitled to receive ratably such dividends, if any, as may be declared
from time to time by the Board. Common Stock holders have no preemptive, conversion or other subscription rights. There are no
redemption or sinking fund provisions related to the Common Stock. In the event of liquidation, dissolution or winding up of the
Company, our Common Stock holders are entitled to share ratably in all assets remaining after payment of liabilities, subject
to prior distribution rights of preferred stock, if any, then outstanding.
Preferred
Stock
We
had no shares of Preferred Stock issued and outstanding as of April 25, 2018.
Warrants
No
warrants are outstanding as April 25, 2018.
Anti-Takeover
Effects of Provisions of the Articles of Incorporation, Bylaws and Nevada Law
Authorized
and Unissued Stock
The
authorized but unissued shares of our Common Stock are available for future issuance without the approval of our stockholders.
These additional shares may be utilized for a variety of corporate purposes including but not limited to future public or direct
offerings to raise additional capital, corporate acquisitions and employee incentive plans. The issuance of such shares may also
be used to deter a potential takeover of the Company that may otherwise be beneficial to our stockholders by diluting the shares
held by a potential suitor or issuing shares to a stockholder that will vote in accordance with the desires of the Board. A takeover
may be beneficial to stockholders because, among other reasons, a potential suitor may offer stockholders a premium for their
shares of stock compared to the then-existing market price.
Nevada
Anti-Takeover Laws
Nevada
Revised Statutes (“NRS”) Sections 78.378 to 78.3793 provide state regulation over the acquisition of a controlling
interest in certain Nevada corporations unless the articles of incorporation or bylaws of the corporation provide that the provisions
of these sections do not apply. Our Articles of Incorporation and Bylaws do not state that these provisions do not apply.
The
statute creates a number of restrictions on the ability of a person or entity to acquire control of a Nevada company by setting
down certain rules of conduct and voting restrictions in any acquisition attempt, among other things. The restrictions on the
acquisition of controlling interests contained in NRS Sections 78.378 to 78.3793 apply only to a Nevada corporation that: (a)
has 200 stockholders of record (at least 100 of whom have addresses in the State of Nevada appearing on the stock ledgers of the
corporation); and (b) does business in the State of Nevada, either directly or through an affiliated corporation. Currently, we
do not have 100 stockholders of record with addresses in the State of Nevada. Furthermore,
we do not conduct business in the State of Nevada and we do not intend to conduct business in the State of Nevada in the near
future. Accordingly, the anti-takeover provisions contained in NRS Sections 78.378 to 78.3793 do not apply to us, and are not
likely to apply to us in the foreseeable future.
Transfer
Agent and Registrar
Empire
Stock Transfer, Inc. is the transfer agent and registrar of our Common Stock and Preferred Stock. Their address is 1859 Whitney
Mesa Drive, Henderson, NV 89014 and their telephone number is (702) 818-5898.
INTEREST
OF CERTAIN PERSONS IN OPPOSITION TO MATTERS TO BE ACTED UPON
(a)
No officer or Director of the Company has any substantial interest in the matters to be acted upon, other than his role as an
officer or Director of the Company.
(b)
No Director in good standing with the Company has informed the Company that he intends to oppose the actions to be taken by the
Company as set forth in this Information Statement.
ADDITIONAL
INFORMATION
Additional
information concerning PetLife Pharmaceuticals, Inc., including its annual and quarterly reports filed with the SEC, may be accessed
through the SEC’s EDGAR archives at www.sec.gov.
PROPOSAL
1 – INCREASE AUTHORIZED NUBMER OF SHARES OF COMMON STOCK OF THE COMPANY
The
Company’s Board proposes to increase the authorized number of shares of Common Stock from Seventy-five Million (75,000,000)
to Ten Billion (10,000,000,000) $0.001 par value per share.
Purpose
of the Increase in Number of Authorized Shares of Common Stock
The
purpose of the proposed increase in the number of authorized shares of common stock is to (i) to provide authorized but unissued
shares which would be available for future acquisitions or capital raising efforts.
Potential
Effects of the Increase in Number of Authorized Shares of Common Stock
The
Company does not believe that there are any potential effects with respect to the increase of the number of authorized shares.
Summary
of Advantages and Disadvantages of Increase in Number of Authorized Shares of Common Stock
There
are certain advantages of voting for the Increase in Number of Authorized Shares. The advantages include:
To
provide authorized but unissued shares which would be available for future acquisitions or capital raising efforts.
There
are certain disadvantages of voting for the Increase in the Number of Authorized Shares of Common Stock. The disadvantages include:
The
authorized but unissued shares of our Common Stock are available for future issuance without the approval of our stockholders.
These additional shares may be utilized for a variety of corporate purposes including but not limited to future public or direct
offerings to raise additional capital, corporate acquisitions and employee incentive plans. The issuance of such shares may also
be used to deter a potential takeover of the Company that may otherwise be beneficial to our stockholders by diluting the shares
held by a potential suitor or issuing shares to a stockholder that will vote in accordance with the desires of the Board. A takeover
may be beneficial to stockholders because, among other reasons, a potential suitor may offer stockholders a premium for their
shares of stock compared to the then-existing market price.
Recommendation
of the Board of Directors
Our
Board unanimously recommended a vote “FOR” the approval to increase the authorized number of shares of Common Stock
from Seventy-five Million (75,000,000) to Ten Billion (10,000,000,000) $0.001 par value per share.
No
Voting of Stockholders Required
We
are not soliciting any votes with regard to the proposal to effectuate the increase in authorized. A certain principal stockholder
that has voted in favor of this Proposal holds 54.3% of the total issued and outstanding voting stock rights and, accordingly,
this principal stockholder has sufficient shares to approve the Proposal.
DELIVERY
OF DOCUMENTS TO SECURITY HOLDERS SHARING AN ADDRESS
Only
one (1) Information Statement is being delivered to multiple security holders sharing an address unless the Company has received
contrary instructions from one or more of the security holders. The Company shall deliver promptly upon written or oral request
a separate copy of the Information Statement to a security holder at a shared address to which a single copy of the documents
was delivered. A security holder can notify the Company that the security holder wishes to receive a separate copy of the Information
Statement by sending a written request to the Company at 10120 So. Eastern Avenue, Suite 213, Henderson, NV 89052; or by calling
the Company at (855) 682-7853 and requesting a copy of the Information Statement. A security holder may utilize the same address
and telephone number to request either separate copies or a single copy for a single address for all future Information Statements
and annual reports.
By
Order of the Board of Directors
/s/
Laura De Leon Castro
|
|
Laura
De Leon Castro, Secretary
|
|
Henderson,
NV 89052
________________,
2018
Petlife Pharmaceuticals (CE) (USOTC:PTLF)
Historical Stock Chart
From Sep 2024 to Oct 2024
Petlife Pharmaceuticals (CE) (USOTC:PTLF)
Historical Stock Chart
From Oct 2023 to Oct 2024